Evolus, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
30052C107
SEDOL
BFZ4SQ3
CIK
0001570562
www.evolus.com
LEI:
©
FIGI: BBG005CX4HK8
EOLS
Evolus, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Drug Manufacturers—Specialty & Generic
AI
PROFILER
NAME
Evolus, Inc.
ISIN
US30052C1071
TICKER
EOLS
MIC
XNAS
REUTERS
EOLS.OQ
BLOOMBERG
EOLS US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Fri, 13.12.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November non-qualified stock options to purchase an aggregate of 9,872 shares of Evolus and an aggregate of 16,596 restricted stock units (RSUs) of the company’s common stock to 9 newly hired non...
Read More
Evolus
Technical Analysis Termsheet Terminal
Permalink
Wed, 06.11.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “Our third quarter results underscore the momentum we’ve been building throughout the year,” said David Moata...
Read More
Evolus
Technical Analysis Termsheet Terminal
Permalink
Fri, 01.11.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET. The presentation can be accessed on the Investor Relations page of the Evolus websi...
Read More
Evolus
Technical Analysis Termsheet Terminal
Permalink
Thu, 31.10.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme® (pronounced “esteem”), branded as Evolysse™ in the U.S. mar...
Read More
Evolus
Technical Analysis Termsheet Terminal
Permalink
Tue, 29.10.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpassed one million enrolled consumers and completed the two-millionth Jeuveau® redemption in its Evolus Rewards™ patient loyalty program. “The achievement of these milestones underscores the ...
Read More
Evolus
Technical Analysis Termsheet Terminal
Permalink
Wed, 23.10.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss...
Read More
Evolus
Technical Analysis Termsheet Terminal
Permalink
Sat, 12.10.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,251 shares of Evolus and an aggregate of 31,049 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non-execut...
Read More
Evolus
Technical Analysis Termsheet Terminal
Permalink
Sat, 28.09.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 10,845 restricted stock units (RSUs) of the company’s common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee ...
Read More
Evolus
Technical Analysis Termsheet Terminal
Permalink
Fri, 06.09.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the company will be ringing the Nasdaq closing bell on Friday, September 13, 2024. The Nasdaq closing bell ceremony is a time-honored tradition, serving as a platform for companies to celebrate achievements and milestones. T...
Read More
Evolus
Technical Analysis Termsheet Terminal
Permalink
Fri, 09.08.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July an aggregate of 46,363 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non-executive employees of the company (the “July Grants”). The Company also is reporting...
Read More
Evolus
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S